|Synonyms||RU-2420; 7α,17α-Dimethyltrenbolone; 7α,17α-Dimethyl-δ9,11-19-nortestosterone; 7α,17α-Dimethylestra-4,9,11-trien-17β-ol-3-one|
|Drug class||Androgen; Anabolic steroid; Progestogen|
|Chemical and physical data|
|Molar mass||298.426 g/mol|
|3D model (JSmol)|
Dimethyltrienolone (developmental code name RU-2420) is a synthetic, orally active, and extremely potent anabolic–androgenic steroid (AAS) and 17α-alkylated 19-nortestosterone (nandrolone) derivative which was never marketed for medical use. It has among the highest known affinity of any AAS for the androgen (and progesterone) receptors, and has been said to be perhaps the most potent AAS to have ever been developed.
Dimethyltrienolone is an extremely potent agonist of the androgen and progesterone receptors and hence AAS and progestogen. In animal bioassays, it was shown to possess more than 100 times the anabolic and androgenic potency of the reference AAS methyltestosterone. The drug is not a substrate for 5α-reductase and so is not potentiated or inactivated in so-called "androgenic" tissues like the prostate gland or skin. It is also not a substrate for aromatase and so has no estrogenic activity. Due to its lack of estrogenicity, dimethyltrienolone has no propensity for causing estrogenic side effects like gynecomastia. Because of its C17α methyl group and very high resistance to hepatic metabolism, dimethyltrienolone is said to be exceedingly hepatotoxic.
|Values are percentages (%). Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, DEXA for the GR, and aldosterone for the MR.|
Dimethyltrienolone, also known as 7α,17α-dimethyl-δ9,11-19-nortestosterone or as 7α,17α-dimethylestra-4,9,11-trien-17β-ol-3-one, as well as 7α,17α-dimethyltrenbolone, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone). It is the 7α,17α-dimethyl derivative of trenbolone and the 7α-methyl derivative of metribolone, as well as the δ9,11 analogue of metribolone and the δ9,11, 17α-methylated derivative of trestolone.
- William Llewellyn (2009). Anabolics. Molecular Nutrition Llc. pp. 212–214. ISBN 978-0967930473.
- Waszkowycz B, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Westhead DR (1994). "PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores". J. Med. Chem. 37 (23): 3994–4002. doi:10.1021/jm00049a019. PMID 7966160.
- Loughney DA, Schwender CF (1992). "A comparison of progestin and androgen receptor binding using the CoMFA technique". J. Comput.-Aided Mol. Des. 6 (6): 569–81. doi:10.1007/bf00126215. PMID 1291626.
- Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity". J. Steroid Biochem. 13 (1): 45–59. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
- Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". J. Steroid Biochem. 27 (1-3): 255–69. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.
- D. Ganten; D. Pfaff (6 December 2012). Actions of Progesterone on the Brain. Springer Science & Business Media. pp. 17–. ISBN 978-3-642-69728-9.
- Mathieu, J (1967). Proceedings of the International Symposium on Drug Research, Montreal, Canada, June 12-14, 1967. Chemical Institute of Canada, Medical Chemistry Group, Montreal, Canada. p. 134.